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Brief Communications
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Zoonotic prion transmission was reported after the bovine spongiform encephalopathy (BSE) epidemic, when 200 cases of prion
disease in humans were diagnosed as variant Creutzfeldt-Jakob disease. Assessing the risk of cross-species prion transmission remains
challenging.We and others have studied how specific amino acid residue differences between species impact prion conversion and have
found that the 2-2 loop region of the mouse prion protein (residues 165–175) markedly influences infection by sheep scrapie, BSE,
mouse-adapted scrapie, deer chronicwastingdisease, andhamster-adapted scrapie prions. The tyrosine residue at position 169 is strictly
conserved amongmammals and an aromatic side chain in this position is essential tomaintain a 310-helical turn in the2-2 loop. Here
we examined the impact of the Y169G substitution together with the previously described S170N, N174T “rigid loop” substitutions on
cross-species prion transmission in vivo and in vitro. We found that transgenic mice expressing mouse PrP containing the triple-amino
acid substitution completely resisted infection with two strains of mouse prions and with deer chronic wasting disease prions. These
studies indicate that Y169 is important for prion formation, and they provide a strong indication that variation of the 2-2 loop
structure can modulate interspecies prion transmission.
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Introduction
Transmission of prion diseases between individuals can be re-
markably efficient and has led to epidemics, as seen with bovine
spongiform encephalopathy (BSE) and chronic wasting disease
(CWD) (Anderson et al., 1996; Miller and Williams, 2003). Dis-
ease occurs when -sheet-rich prion protein aggregates, known
as PrPSc, template the conversion of the normal cellular prion
protein, PrPC, in an autocatalytic process (Prusiner, 1982). Al-
though the mechanism of PrP conversion is not yet clear, single-
residue differences between PrPSc and host PrPC have been
reported to inhibit prion replication (Priola and Chesebro, 1995;
Kaneko et al., 1997; Perrier et al., 2002).
The cellular mouse prion protein consists of a flexibly dis-
ordered 100-residue amino-terminal domain and a globular
C-terminal domain of similar size, which includes three-helices
and a short -sheet (Riek et al., 1996, 1997). Although the overall
architecture of the globular domain is highly conserved, NMR
studies revealed structural variations in the 2-2 loop region
(residues 165–175) among mammalian PrPs. Specifically, at
20°C, the 2-2 loop is disordered in the NMR structures of
PrPC from mouse, cattle, and humans (Riek et al., 1996; Lo´pez
Garcia et al., 2000; Zahn et al., 2000). Elk, bank vole, and horse
PrPCs display a structurally well-defined 2-2 loop at 20°C
(Gossert et al., 2005; Christen et al., 2008; Pe´rez et al., 2010) and
have been referred to as “rigid loop PrPCs” (RL-PrPC). Inserting
the 2-2 loop sequences of elk, bank vole, or horse PrP into
mouse PrP results in hybrid mouse prion proteins showing RL-
PrPC behavior (Gossert et al., 2005; Christen et al., 2008; Pe´rez et
al., 2010).
We have previously found that the 2-2 loop structure pro-
foundly impacts interspecies prion transmission. Transgenic
mice expressing a mouse PrP variant with the elk substitutions
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S170N and N174T [Tg(MoPrP170,174)] showed a prolonged incu-
bation periodwhen exposed tomouse-adapted prions, indicating
a transmission barrier (Sigurdson et al., 2010). Wild-type (WT)
mice are relatively resistant to infection with CWD or hamster
prions (Race et al., 2002; Raymond et al., 2007) yet are suscep-
tible to infection with sheep scrapie and BSE (Hill et al., 1997;
Bruce et al., 2002). Tg(MoPrP170,174) mice showed a complete
switch in species barriers, in that the mice were susceptible to
prions from deer and hamsters, which contain N170, but resisted
infection with prions from sheep and cattle, which contain S170
(Sigurdson et al., 2010). In contrast, the D167S substitution in
mouse PrP (Pe´rez et al., 2010), which also results in RL-PrPC
behavior, had no effect on prion species barriers in transgenic
mice (Bett et al., 2012), suggesting that in this case a primary
sequence variation determines the ease of interspecies prion
transmission.
Recent NMR studies revealed the reason for the poor struc-
tural definition of the 2-2 loop in PrPCs of many mammals,
showing that there is a conformational equilibrium between two
different loop structures (i.e., a 310-helix turn and a type I-turn)
(Damberger et al., 2011; Christen et al., 2012, 2013). In prion
proteins showing a structurally poorly defined loop, the exchange
between the two forms at 20°C is sufficiently slow to broaden the
NMR signals beyond detection, whereas in RL-PrPCs, the ex-
change is sufficiently rapid to observe the dominant 310-helix
form. Replacement of Y169 with glycine results in a PrPC con-
taining only the type I -turn loop structure (Damberger et al.,
2011). These observations on PrPC structures provided the basis
for the present investigations of the effect from this rather dra-
matic local conformational change on the ease of interspecies
transmission of TSEs. To this end, we investigated the conversion
of variant mouse PrP containing the amino acid substitutions
Y169G, S170N, and N174T by a variety of infectious prions from
different species.
Materials andMethods
Generation of transgenic mice expressing MoPrP169,170,174. Single-point
mutations that alter the amino acid sequence of the mouse to 169G,
170N, and 174T were generated within a pMECA subclone, based on
pHGPrP (Fischer et al., 1996), using the Stratagene pointmutagenesis kit
(primers: forward, 5-GGCCA GTG GAT CAG GGC AAC AAC CAG
AACACCTTCGTGCACGAC-3 and rc 5-GTCGTGCACGAAGGT
GTTCTGGTTGTTGCCCTGATCCACTGGCC-3). The PmeI/NheI
pMECA subclone was then cloned into the PmeI/NheI sites of the pHG-
PrP plasmid, and the entire ORF was sequenced (Rosenberg et al., 1977).
The Prnpminigene sequence was excised with NotI/SalI, and constructs
were microinjected into the pronucleus of fertilized B6;129S5-Prnp/o
oocytes (Prnp-KO Zurich I) using conventional methods (Ru¨licke,
2004). Founder lines were identified by PCR for the transgene as previ-
ously described (Sigurdson et al., 2011), and founders were bred to
Prnpo/omice. Nine transgene-carrying foundermice were identified that
transmitted the transgene to their progeny; Tg(Prp 169,170,174)70–91Biat.
Lines were maintained by crossing with Prnpo/o mice. Mice were main-
tained under specific pathogen-free conditions.
Prion inoculations. WT (C57BL/6), Tg(MoPrP169,170,174), or Tga20
transgenic mice (groups of n  4–6 mice) of either sex were intracere-
brally inoculated into the left parietal cortex with 30 l of brain homog-
enate containingRMLor 22Lmouse scrapie prions, orCWDprions from
a naturally infected mule deer previously shown to contain infectious
prions (Sigurdson et al., 2006). Uninfected brain homogenate was inoc-
ulated into the same mouse genotypes as a negative control. Mice were
monitored three times weekly, and TSE was diagnosed according to clin-
ical criteria, including ataxia, kyphosis, stiff tail, hind leg clasp, and hind
leg paresis. Mice were killed at the onset of terminal disease when show-
ing signs including weight loss, tremors, slow movements, and severe
kyphosis, or by 600 d after inoculation. Incubation period was calcu-
lated from the day of inoculation to the day of terminal clinical disease.
Sodium phosphotungstic acid (NaPTA) precipitation and Western blot-
ting. A total of 10% brain homogenates from all prion-inoculated mice
were prepared in PBS using a Beadbeater tissue homogenizer. Samples
were subjected to NaPTA precipitation as previously described (Wads-
worth et al., 2001).
PrP peptide ELISA. The peptide ELISA was performed as described by
Lau et al. (2007) with minor modifications. PrP was measured by stan-
dard sandwich ELISA on a 96-well plate precoated with 2.5 g/ml
POM-2 antibody. A biotinylated POM-1 antibody (50 ng/ml) followed
by streptavidin HRP and an Ultra TMB-ELISA substrate (Thermo Sci-
entific) was used for detection. RML-infected and uninfected control
brain samples were included in every experiment. Samples were run in
triplicate.
Histopathology and immunohistochemical stains. Two-micron-thick
sections were stained with hematoxylin and eosin or immunostained
using antibodies for PrP as previously described (Bett et al., 2012).
Protein misfolding cyclic amplification (PMCA). The in vitro prion rep-
lication and PrPSc detection of amplified samples was performed as pre-
viously described (Castilla et al., 2008). Briefly, 50 l of brain
homogenate was seeded with 5 l of each of prion seed and subjected to
sonication in a sonicator water bath at 37°C-38°C. The sonicator settings
were as follows: 20 s at power setting 70%–80% followed by 30 min of
incubation (model S-700MPX, QSonica). Three serial rounds of PMCA
were performed, and all sonicated samples were digested with 50–100
g/ml of PK for 1 h at 42°C. To test for PrPSc in L87 mice, each brain
homogenate was subjected to 4 experimental repetitions, each per-
formed with four replicates. Blots were probed with monoclonal anti-
bodies 6D11 or 6H4.
Results
Mouse characterization
We developed transgenic mice that express variant murine PrPC
with the Y169G, S170N, and N174T substitutions under the
prion promoter.Nine lines ofTg(MoPrP169,170,174)were bred on a
PrP knock-out background and found to have onefold to twofold
PrPC expression levels in the brain compared with WT mice.
Because PrP function can be assessed only indirectly, we tested
whether mutant PrP functions similarly to WT PrP in rescuing
early death in mice expressing amino-terminally truncated PrP
(F35) (Shmerling et al., 1998). MoPrP169,170,174 rescued the early
death of the F35 mice, similar to WT MoPrP (F35: 92  6 d;
F35/WT: 259 15 d; F35/MoPrP169,170,174: 207 25 d; mean
SE; n 5–9/group).
Line 87 (L87) mice, which expressed PrP at slightly less than
WT levels (data not shown), were selected for prion inoculation
experiments. MoPrP170,174 is aggregation-prone and leads to a
spontaneous transmissible spongiform encephalopathy, with
prion plaques in the brain and skeletal muscle of aged mice (Sig-
urdson et al., 2009). Here, we did not observe spontaneous prion
disease or plaques in the brain of aged L87 mice.
Table 1. Incubation period of Tg(MoPrP 169,170,174) andWTmice inoculated with
mouse or cervid CWD prions
Inoculum Genotype
Incubation period
(mean SE days)a
Attack
rate
RML WT 163 4 5/5
Tg(MoPrP 169,170,174) 384 43 0/5
22L WT 131 2 5/5
Tg(MoPrP 169,170,174) 365 29 0/5
CWD WT 638 3 0/4
Tg(MoPrP 169,170,174) 515 35 0/5
aAll but one of the Tg(MoPrP 169,170,174)mice were more than 500 d of age when they were euthanized because of
concurrent disease. No brain lesions or PrP Sc was evident in these animals.
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Species barriers to mouse prions
We assessed the impact of the Y169G, S170N, andN174T residue
exchanges on prion conversion in vivo. Tg(MoPrP169,170,174) and
WT mice were intracerebrally inoculated with RML mouse pri-
ons on the same day. WTmice developed prion disease by 173 d,
whereas none of the RML-exposed Tg(MoPrP169,170,174)mice de-
veloped clinical signs of prion disease, after up to 466 d after
inoculation (Table 1), or showed any evidence of prion infection
in the brain by Western blotting using sodium phosphotungstic
acid precipitation or PrP immunohistochemistry (Fig. 1A,B).
Mild vacuolation was apparent in brains of some Tg(Mo-
PrP169,170,174)mice.We considered the possibility that these mice
had developed PK-sensitive multimers of PrP. We therefore
tested for PrP aggregates using a PrP-peptide ELISA assay (Lau
et al., 2007), but no PK-sensitive PrP aggregates were revealed
in the Tg(MoPrP169,170,174) mice (Fig. 1C). PrPSc is readily de-
tected in the brains of mice expressing 50% of WT PrPc levels at
200 d after inoculation with RML (C.J.S., unpublished data),
indicating that the absence of PrPSc in Tg(MoPrP169,170,174)mice
was not due to the slightly lower PrPc expression levels.
Because the PrPSc conformation impacts the conversion effi-
ciency of PrPC (Telling et al., 1996; Atarashi et al., 2006), we
tested a second mouse-adapted prion strain known as 22L.
Whereas the WTmice were highly susceptible to 22L mouse pri-
ons, the Tg(MoPrP169,170,174) mice resisted infection after up to
529 d post inoculation, and they did not reveal any evidence of
PrPSc by peptide ELISA,Western blot, or PrP immunostaining of
brain sections (Fig. 1C–E; Table 1).
Species barriers to deer prions
Transgenic mice that express mouse PrP with a 2-2 loop ho-
mologous to deer and elk [Tg(MoPrP170,174)] are susceptible to
deer CWDprions (Sigurdson et al., 2010). To determine whether
the additional Y169G substitution would affect CWD suscepti-
bility, we inoculatedTg(MoPrP169,170,174) andWTmice, as well as
Tga20mice as previously reported, with deer CWD (Sigurdson et
al., 2006, 2010). However, unlike Tg(MoPrP170,174) and Tga20
mice, the Tg(MoPrP169,170,174)mice completely resisted infection
with the same CWD inoculum, suggesting that the Y169G sub-
stitution contributed to a species barrier to CWD (Fig. 1F; Table
1). Thus,MoPrP169,170,174was not converted by either two strains
of mouse prions or by deer prions.
Confirming absence of prion propagation in
Tg(MoPrP169,170,174)mice
To assess whether low levels of PrPSc exist in the brains of the
Tg(MoPrP169,170,174)mice inoculated with mouse or deer prions,
we performed serial PMCA to detect PrPSc that may have been
present at low levels (Saa´ et al., 2006). PrPC substrate from unin-
fected Tg(MoPrP169,170,174) or healthy WT mouse brain was
seeded with prion-exposed Tg(MoPrP169,170,174)mouse brain ho-
mogenate, and the samples were subjected to three serial rounds
(24 h per round) of PMCA. None of the brain samples from the
prion-exposed Tg(MoPrP169,170,174) mice showed any detectable
PK-resistant PrP with either of the substrates used, whereas
RML- and 22L-infectedWTbrain samples showed efficient PrPSc
amplification inWT substrate after one round of PMCA (Fig. 2).
Figure 1. Tg(MoPrP169,170,174) mice inoculated with mouse or deer prion-infected brain show no PrP Sc accumulation in the brain by Western blot, ELISA, or PrP immunohistochemistry. Brain
homogenates from Tg(MoPrP169,170,174), WT, or Tga20 mice, which had been inoculated with mouse prions (RML, 22L), deer prions (CWD), or uninfected brain (mock), were subjected to NaPTA
precipitation and Western blotting. PrP Sc is seen only in WT and Tga20 mice expressing mouse PrP (A, D, F ). A, Western blot of RML-inoculated Tg(MoPrP169,170,174) mice at 384–466 d after
inoculation. B, Brain at hippocampus shows no PrP Sc deposits in the Tg(MoPrP169,170,174) mice inoculated with RML. C, Peptide ELISA reveals no PK-sensitive PrP Sc in Tg(MoPrP169,170,174) mice
inoculated with RML, 22L, or CWD, whereas PrP Sc was present in WT mice inoculated with RML or 22L prions. WT mice resisted infection with deer CWD. D, Western blot of 22L-inoculated
Tg(MoPrP169,170,174)mice at 378–529 d after inoculation. E, Brain at hippocampus shows no PrP Sc deposits in the Tg(MoPrP169,170,174)mice inoculated with 22L. Western blot of CWD-inoculated
Tg(MoPrP169,170,174)mice at 493–618 d after inoculation. A, D, F, The negative control shows the PrP signal from the brain of a Tg(MoPrP169,170,174)mouse.
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In one of four experiments, there was a very low level of conver-
sion in one of four replicate samples of Tg(MoPrP169,170,174) sub-
strate directly seededwith RMLor 22L after three rounds of serial
PMCA.
Species barriers to cattle, sheep, or hamster prions
Because neither mouse nor deer prions could detectably convert
MoPrP169,170,174 in vivo, suggesting a strong species barrier, we fur-
ther tested whether MoPrP169,170,174 could be converted by prions
fromcattle, sheep, or hamsters using thePMCAassay.As a source of
PrPC, we used brain homogenate from Tg(MoPrP169,170,174) or WT
mice. To determine whether any PrPSc could be amplified in the Tg-
(MoPrP169,170,174) substrate, we performed three serial rounds of
PMCA amplification. The WT mouse substrate amplified PrPSc
from 263K hamster scrapie after 2 rounds, and from sheep scrapie
and cattle BSE after 3 amplification rounds. Remarkably, neither
prions from sheep, cattle, or hamster, nor from deer, converted
MoPrP169,170,174, even after 3 rounds of PMCA (Fig. 3).
Discussion
Here we found that transgenic mice expressing a variant mouse
PrP containing the three amino acid substitutions S170N,
N174T, and Y169G in the 2-2 loop completely resisted infec-
tion with two different strains of mouse prions. The previously
generated “rigid loop” mice, which express mouse PrP with the
S170N and N174T substitutions, were susceptible to mouse pri-
ons, whereby all mice developed prion disease with prolonged
and variable incubation periods indicative of a transmission bar-
rier (Sigurdson et al., 2010). The additional replacement of the
strictly conserved tyrosine in the 2-2 loop with glycine now
abolished all conversion in the Tg(MoPrP169,170,174) mice. There
was no detectable PrPSc in the brain of any of these mice, even
after incubation periods of up to 466 d, whereas the WT mice
developed disease after 173 d. Together, these results suggest that
the added substitution of Y169G had a profound inhibitory effect
on TSE transmission.
The Tg(MoPrP170,174) mice were 100% susceptible to CWD;
however, the Tg(MoPrP169,170,174) mice showed no detectable
CWD prion infection in vivo or in vitro. The Tg(MoPrP170,174)
mice express higher PrPC levels than the Tg(MoPrP169,170,174)
mice, so there was the possibility that differences in CWD suscep-
tibility were due to different PrPC expression levels. However,
this is highly unlikely, as three rounds of PMCA also failed to
show PrP conversion. We also tested
whether the MoPrP169,170,174 could be
converted by hamster, cattle, or sheep pri-
ons and found no conversion of the Mo-
PrP169,170,174 seeded by any of these prions
in three rounds of the PMCA assay.
Therefore, none of the prions from four of
detectable conversion of MoPrP169,170,174.
Mouse prions successfully converted one of
four replicates of MoPrP169,170,174, suggest-
ing that the barrier to mouse prions is
weaker than the barrier to prions from the
other four species. Three rounds of PMCA
were performed to robustly compare the
Tg(MoPrP169,170,174) with the WT substrate
yet avoid false positive signals fromspontane-
ous conversion (three PMCA rounds have
previously replicated known species barriers)
(Kurt et al., 2009). It remains possible that
MoPrP169,170,174 might be converted by pri-
ons through further PMCArounds.
Few single-residue substitutions in PrPC have been reported
to completely abolish prion infection. The E219K substitution
may delay or prevent prion infection in humans and mice, de-
pending on the prion strain and the genetic background of the
mice (Perrier et al., 2002; Hizume et al., 2009). G96S inhibits
CWD infection in a transgenic mouse model (Meade-White et
al., 2007), yet there are CWD-infected deer expressing PrP with
serine in position 96 (Johnson et al., 2006). Transgenic mice ex-
pressing mouse PrP with the single Q168R 2-2 loop substitu-
tion showa complete barrier to infectionwithRMLmouse prions
(Perrier et al., 2002). The Q172R substitution, which also lies
within the 2-2 loop, potently inhibits in vitro conversion by
mouse or hamster prions (Geoghegan et al., 2009).
Because the substitution of Y169 in MoPrP with glycine re-
sults in a quite dramatic local change of themolecular conforma-
tion, where the 2-2 loop forms a type I -turn and there is no
evidence for a dynamic admixture of other significantly popu-
lated structures (Damberger et al., 2011; Christen et al., 2013), the
present data show that, in addition to the primary structure ef-
fects indicated by studies of different variant PrPs (see above), the
conformation of the2-2 loop in PrPCmay also impact the ease
of TSE transmission between different species. We await with
interest the results of in vivo experiments (in progress in one of
our laboratories) with transgenic mice expressing MoPrP with
different single-amino acid substitutions in position 169. Because
these substitutions result either in an apparently “pure” type I
-sheet turn structure or in maintaining the dynamic equilib-
riumbetween two loop structures (Damberger et al., 2011; Chris-
ten et al., 2012; Christen et al., 2013), as observed in natural PrPCs
of mammalian species, these experiments should provide addi-
tional information on the apparently intricate interplay between
the amino acid sequence of the 2-2 loop and its conformation
in their effects on TSE transmission.
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